Anika therapeutics inc..

On April 26, 2023, the board of directors, or the Board, of Anika Therapeutics, Inc., or the Company, adopted and approved, subject to stockholder approval, an amendment, or the Amendment, to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan as previously amended, or the 2017 Plan.

Anika therapeutics inc.. Things To Know About Anika therapeutics inc..

Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care.The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.Anika Therapeutics, Inc. Kristen Galfetti, 781-457-9000 Executive Director, Investor Relations [email protected] : For Media Inquiries: W2O Group Rachel Girard, 617-379-6760 [email protected] Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people ...Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.

Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people ...Solutions to help restore active living. We offer a range of minimally invasive solutions in joint preservation and restoration that are designed to restore active living for patients around the world. Solutions to help restore active living. We offer a range of minimally invasive solutions in joint preservation and restoration that are designed to restore active living for patients around the world.

Anika Therapeutics, Inc.: study sponsor, Dr. Laszlo Hangody: global principal investigator, SynteractHCR: CRO. Anika is a global joint preservation company committed to delivering meaningful advancements in early intervention orthopedic care, including osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface ...BEDFORD, Mass. -- (BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced it has received marketing approval for MONOVISC® from the U.S. Food and Drug Administration (FDA). MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients ...

Pursuant to the Anika Therapeutics, Inc. 2003 Stock Option Incentive Plan (the “Plan”) as amended through the date hereof, Anika Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, …In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this process is the family genogram.ANIKA THERAPEUTICS APPOINTS LIFE SCIENCES VETERAN RAYMOND J. LAND TO BOARD OF DIRECTORS . Woburn, Mass.– January 25, 2006 – Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has appointed Raymond J. Land as a new independent director on the company’s board. Land will become the chairperson of the …Oct 10, 2023 · BEDFORD, Mass., November 7, 2023 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard,... Nov 2, 2023 Anika Reports Third Quarter 2023 Financial Results

Anika is a global joint preservation company committed to delivering meaningful advancements in early intervention orthopedic care, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies.

1992. Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc. Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc ® and Amvisc ® Plus. Brought to Anika through the acquisition of Arthrosurface, Inc.

Feb 21, 2023 · Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people ...Hayward Pool Products Inc is a leading manufacturer of high-quality pool equipment, including pumps, filters, heaters, and cleaners. If you’re lucky enough to own one of their products, it’s important to keep it in good condition to ensure ...May 9, 2023 · Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people ... Anika Therapeutics, Inc. # 023-05370 (d) For purposes of this Confirmation: (i) Address for notices or communications to Issuer: Anika Therapeutics, Inc. 32 Wiggins Avenue. Bedford, MA 01730. Attention: Sylvia Cheung. Telephone: 781-457-9214. Facsimile: 781-305-9720. Email Address: [email protected] . With a copy to: Anika ...

About Anika Therapeutics ... An orthopedic pharmaceutical company popularly known for its products Orthovisc and Monovisc, their aim is to improve life naturally.Anika’s Shoulder HemiCAP ® Systems and the OVO ® /OVOMotion ® with Inlay Glenoid Shoulder Arthroplasty Systems are minimally invasive solutions for treating patients suffering from glenohumeral osteoarthritis, across glenoid stages. The non-spherical humeral head implants with inlay glenoid precisely recreate the native anatomy of the ...Anika Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 035255108 (CUSIP Number) David Johnson: Caligan Partners LP: 515 Madison Avenue, 8 th Floor: New York, NY 10022 (646) 859-8204 : Eleazer Klein, Esq. Adriana Schwartz, Esq. Schulte Roth & Zabel LLP: 919 Third Avenue: New York, NY ...Please refer to the Instructions for Use for a complete list of indications, contraindications, warnings, and precautions. ORTHOVISC® is a registered trademark and manufactured by ANIKA Therapeutics, Inc.Anika Therapeutics, Inc. is a joint preservation company. The Company is engaged in creating and delivering advancements in early intervention orthopedic care, including osteoarthritis (OA) pain ...As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...

BEDFORD, Mass., November 7, 2023 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard,... Nov 2, 2023 Anika Reports Third Quarter 2023 Financial Results

Apr 13, 2023 · For Investor Inquiries: Anika Therapeutics, Inc. Mark Namaroff, 781-457-9287. Vice President, Investor Relations, ESG and Corporate Communications. [email protected]. For Media Inquiries: Jamie Moser / Tanner Kaufman. Joele Frank, Wilkinson Brimmer Katcher. 212-355-4449. Dr. Blanchard joined the Board of Directors of Anika Therapeutics, Inc. in August 2018, serving on the Company’s Compensation Committee and Governance and Nominating Committee. Prior to her work as an executive officer with Anika, she served as the President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed ...ANIKA THERAPEUTICS, INC. 32 Wiggins Avenue Bedford, MA 01730 – USA Phone: +1-781-457-9000 Fax: +1-781-305-9720 Email: [email protected] ANIKA THERAPEUTICS S.R.L. Corso Stati Uniti 4/UAnika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Mass. Anika is committed to delivering therapies to improve ...Item 1.01 Entry into a Material Definitive Agreement. On January 31, 2008, Anika Therapeutics, Inc. (the “Company”) entered into a Credit Agreement (the “Agreement”) dated as of January 31, 2008, among the Company, as borrower, Anika Securities, Inc., a wholly owned subsidiary of the Company, as guarantor, each of the lenders from time to …Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers meaningful advancements in early intervention orthopedic care, as well as develops minimally ... Anika Therapeutics, Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early …

Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of ...

Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Massachusetts . 000-21326 . 04-3145961 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 160 New Boston Street, Woburn, Massachusetts .

Anika Therapeutics, Inc. Mark Namaroff, 781-457-9287 Executive Director, Investor Relations and Corporate Communications [email protected]. For Media Inquiries: Greenough Christine Williamson, 617-922-1289 Senior Vice President [email protected] . Source: Anika Therapeutics Inc.May 20, 2022 · Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core ... Item 1.02. Termination of a Material Definitive Agreement. On December 29, 2016, Anika Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) (“Anika S.r.l”), the wholly-owned Italian subsidiary of Anika Therapeutics, Inc. (together with Anika S.r.l., the “Company”) notified Fidia Farmaceutici S.p.A. (“Fidia”) of its intention to terminate the …For Investor Inquiries: Anika Therapeutics, Inc. Mark Namaroff, 781-457-9287. Vice President, Investor Relations, ESG and Corporate Communications. [email protected]. For Media Inquiries: Jamie Moser / Andrew Siegel / Tanner Kaufman. Joele Frank, Wilkinson Brimmer Katcher. 212-355-4449.BEDFORD, Mass., August 17, 2023 — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, …Anika Therapeutics Inc. Common Stock (ANIK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Arthrosurface joint solutions customer service. +1-866-261-9294. [email protected]. Sports medicine customer service. +1-877-746-2972. [email protected]. Hyalofast and international customer service. [email protected] Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people ...Operator. Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. (Operator Instructions) Please note, today's event is being recorded. I'd now like ...Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core ...

Sep 1, 2021 · Anika Therapeutics, Inc. Mark Namaroff, 781-457-9287 Executive Director, Investor Relations and Corporate Communications [email protected] . For Media Inquiries: Greenough Christine Williamson, 617-922-1289 Senior Vice President [email protected] . Source: Anika Therapeutics Inc. Anika’s Patellofemoral Arthroplasty Systems are designed to restore the native shape of the Patella and Femoral Trochlea Groove while preserving native joint anatomy. This creates a congruent pathway by using an intraoperative 3-dimensional mapping system with anatomically designed implants. The PF HemiCAP ® Classic, PF Wave ® & …Pursuant to the Anika Therapeutics, Inc. 2003 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Anika Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the …Instagram:https://instagram. croc stocksgambling companiescgdv etfenergy fuels stock Jun 5, 2023 · Anika Therapeutics, Inc. is one important step closer to FDA approval of its novel hyaluronic acid (HA) matrix, single-stage, bone-preserving, regenerative knee cartilage repair product. This leader in early intervention joint preservation technologies, announced this week that researchers had completed a pivotal Phase III clinical study for ... 5dollar stockswhat's the value of a 1964 kennedy half dollar The global osteoarthritis therapeutics market is forecast to reach $11.2 billion by 2026 from $7.4 billion in 2021 at a compound annual growth rate (CAGR) of 8.6% for the forecast period of 2021 ... data center investment opportunities Hyaluronic Acid Industry Overview. The global hyaluronic acid market size was valued at USD 8.5 billion in 2020 and is expected to reach USD 14.4 billion by 2028, expanding at a CAGR of 7.19% over the forecast period.The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.